The therapeutic effectiveness of oral cannabidiol in addition to current treatment in cats with osteoarthritis

Article type: Review Article

Keywords: cannabinoid, cannabidoil, cat, cbd, feline, locomotion, oa, osteoarthritis, pain

Authors: Oliver Wilkinson ⚬

Affiliations: University of Bristol, United Kingdom

License: Copyright (c) 2024 Oliver Wilkinson CC BY 4.0 Veterinary Evidence uses the Creative Commons copyright Creative Commons Attribution 4.0 International License. That means users are free to copy and redistribute the material in any medium or format. Remix, transform, and build upon the material for any purpose, even commercially – with the appropriate citation.

Article links: DOI: 10.18849/ve.v9i4.691  |  PubMed: 42004287  |  PMC: PMC12710401

Relevance: Relevant: mentioned in keywords or abstract

Full text: PDF (130 KB)

How to apply this evidence in practice

The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.

Knowledge Summaries are a resource to help reinforce or inform decision-making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.

Clinical scenario

An owner presents a 10-year-old cat with diagnosed osteoarthritis (OA) causing chronic pain, which is on long-term NSAIDs for analgesia. However, the cat is still showing signs of discomfort. The owner is unable to afford monoclinal antibody treatment (frunevetmab) and enquires about the effectiveness of cannabidiol (CBD) as an additional supplement.

The evidence

There is no peer-reviewed evidence in cats that meets the inclusion criteria of the PICO.

Appraisal, application and reflection

OA is a common condition seen in older companion animals, with numerous useful first-line treatments in both cats and dogs. However, none of these are 100% risk-free and those with less risk are also expensive in the long term. There has been a lot of research published in recent years into the use of cannabis and CBD in humans for analgesia but a very limited amount in dogs, and none in cats.

Of the papers found, only one paper presented any data regarding cats (Milevoj et al., 2022). However, the data set does not relate to the PICO, as while there are results regarding cats, none are related to OA. The results were also generated by owner surveys so therefore are likely to be subjective, being based on owner views, and, with only 4 responses in cats, the results cannot be considered representative or exhaustive.

A recent case study (Gutierre et al., 2023) suggested that CBD could be used as a therapeutic alternative for cats with OA. However, the CBD mixture contained 0.8% THC (Tetrahydrocannabinol), so cannot be compared to other studies (and is impossible to replicate legally in multiple countries due to controlled drug regulations). A solo case study provides poor evidence of the effectiveness of CBD. In addition, the cat was also on prednisolone and had several concurrent health conditions, so would not have been a good candidate for study into the effectiveness of CBD.

The other studies identified, relating to CBD use in cats, were focusing on safe dosage levels and potential side effects, but none investigated therapeutic outcomes (Kulpa et al., 2021; Wang et al., 2022).

There appears to be weak evidence for CBD being effective in dogs with OA (Gamble et al., 2018; Verrico et al., 2020; Mejia et al., 2021). These papers conclude that more robust studies with increased sample sizes are needed to provide sufficient evidence as to the effectiveness of CBD in OA in either species. The most recent study (Patikorn et al., 2023) also concluded that CBD is considered safe to use in dogs and may reduce pain scores but to be certain more high-quality randomised controlled studies are needed.

Eight papers were identified by a database search, three were review articles, and the other five were not relevant. Most papers focused on dogs and only two papers had any data pertaining to cats which was not relevant to the PICO. Overall, none of the papers qualified for inclusion.

The author did a broader search based on the strategy below (including only species and intervention) to ensure no papers were missed. This resulted in 54 papers; however, all were screened out under exclusion categories listed.

Methodology

Acknowledgements

The author wishes to acknowledge Emma Place, Subject Librarian at the University of Bristol, and Ellie Sellers, Clinical Demonstrator, who gave great support and guidance.

ORCiD

Oliver Wilkinson: https://orcid.org/0009-0006-1992-4694

Conflict of interest

The author declares no conflicts of interest.

References

1. L.-J. Gamble, J.M. Boesch, C.W. Frye, W.S. Schwark, S. Mann, L. Wolfe, Holly Brown, E.S. Berthelsen, J.J. Wakshlag. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Frontiers in Veterinary Evidence, 2018. [DOI]
2. E. Gutierre, N. Crosignani, C. García-Carnelli, A. Mateo., L. Recchi. A case report of CBD and THC as analgesic therapy in a cat with chronic osteoarthritic pain. Veterinary Medicine and Science, 2023. [DOI]
3. J.E. Kulpa, L.J. Paulionis, G.M. Eglit, D.M. Vaughn. Safety and tolerability of escalating cannabinoid doses in healthy cats. Journal of Feline Medicine and Surgery, 2021. [DOI]
4. S.Duerr Mejia, Griffenhagen F.M.D., S. McGrath. Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: A pilot study in dogs. Journal of the American Animal Hospital Association, 2021. [DOI]
5. N. Milevoj, N. Tozon, K. Tomsič. Use of cannabidiol products by pet owners in Slovenia: A survey-based study. Slovenian Veterinary Research, 2021. [DOI]
6. C.Nerapusee Patikorn, Soontornvipart O., Musipodok K., Waleethanaphan K., P. Anantachoti.. Efficacy and safety of cannabidiol for the treatment of canine osteoarthritis: a systematic review and meta-analysis of animal intervention studies. Frontiers in Veterinary Science, 2023. [DOI]
7. A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. 2020. [DOI]
8. T. Wang, A. Zakharov, B. Gomez, A.Trottier Lyubimov., Schwark N.L., J.J. Wakshlag. Frontiers in Veterinary Science). Serum Cannabinoid 24 h and 1 Week Steady State Pharmacokinetic Assessment in Cats Using a CBD/CBDA Rich Hemp Paste. [DOI]